Chardan reiterates Buy on Ocular Therapeutix, $23 target
Chardan Capital maintained a Buy rating on Ocular Therapeutix and set a $23.00 price target, implying 125.7% upside versus the Sep 15 close of $10.19.
Chardan Capital kept its Buy rating on Ocular Therapeutix and maintained a $23.00 price target. The target implies 125.7% upside from the Sep 15 close of $10.19. Key takeaways from the analyst note included a positive regulatory outlook: Ocular Therapeutix recently had a favorable Pre-NDA meeting.